Titan Pharmaceuticals (NASDAQ:TTNP) Now Covered by Analysts at StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP) in a research report issued on Wednesday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Stock Performance

Shares of TTNP stock opened at $3.94 on Wednesday. The firm has a fifty day moving average of $3.68 and a 200-day moving average of $3.96. The stock has a market cap of $3.60 million, a price-to-earnings ratio of -0.76 and a beta of 1.19. Titan Pharmaceuticals has a 52-week low of $3.03 and a 52-week high of $14.80.

Titan Pharmaceuticals (NASDAQ:TTNP) last posted its quarterly earnings results on Thursday, March 20th. The specialty pharmaceutical company reported ($0.85) earnings per share (EPS) for the quarter.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.